A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

Quiroz-Reyes,Adriana G.; González-Villarreal,Carlos A.; Martínez-Rodriguez,Herminia; Said-Fernández,Salvador; Salinas-Carmona,Mario César; Limón-Flores,Alberto Y.; Soto-Domínguez,Adolfo; Padilla-Rivas,Gerardo; Montes De Oca-Luna,Roberto; Islas,Jose F.; Garza-Treviño,Elsa N.

doi:10.3892/mmr.2022.12722

A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

Authors:
- Adriana G. Quiroz-Reyes
- Carlos A. González-Villarreal
- Herminia Martínez-Rodriguez
- Salvador Said-Fernández
- Mario César Salinas-Carmona
- Alberto Y. Limón-Flores
- Adolfo Soto-Domínguez
- Gerardo Padilla-Rivas
- Roberto Montes De Oca-Luna
- Jose F. Islas
- Elsa N. Garza-Treviño
View Affiliations

Affiliations: Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 64460, Mexico, Laboratory of Molecular Genetics, Department of Basic Sciences, University of Monterrey, Monterrey, Nuevo León 66238, Mexico, Department of Immunology, Faculty of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 64460, Mexico, Department of Histology, Faculty of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 64460, Mexico
Published online on: April 29, 2022 https://doi.org/10.3892/mmr.2022.12722
Article Number: 206
Copyright: © Quiroz-Reyes et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As the understanding of cancer grows, new therapies have been proposed to improve the well-known limitations of current therapies, whose efficiency relies mostly on early detection, surgery and chemotherapy. Mesenchymal stem cells (MSCs) have been introduced as a promissory and effective therapy. This fact is due to several useful features of MSCs, such as their accessibility and easy culture and expansion in vitro, and their remarkable ability for ‘homing’ towards tumors, allowing MSCs to exert their anticancer effects directly into tumors. Additionally, MSCs offer the practicability of being genetically engineered to carry anticancer genes, increasing their specificity and efficacy for fighting tumors. In the present study, the antitumoral efficacy and post-implant survival of mice bearing lymphomas implanted intratumorally were determined using mouse bone marrow-derived (BM)-MSCs transduced with soluble TRAIL (sTRAIL), full length TRAIL (flTRAIL), or interferon β (IFNβ), naïve BM-MSCs, or combinations of these. The percentage of surviving mice was determined once all not-implanted mice succumbed. It was found that the percentage of surviving mice implanted with the combination of MSCs-sTRAIL and MSCs-IFN-β was 62.5%. Lymphoma model achieved 100% fatality in the non-treated group by day 41. On the other hand, the percentage of surviving mice implanted with MSCs-sTRAIL was 50% and with MSCs-INFβ 25%. All the aforementioned differences were statistically significant (P<0.05). In conclusion, all implants exhibited tumor size reduction, growth delay, or apparent tumor clearance. MSCs proved to be effective anti-lymphoma agents; additionally, the combination of soluble TRAIL and IFN-β resulted in the most effective antitumor and life enlarging treatment, showing an additive antitumoral effect compared with individual treatments.

View Figures

View References

1	Urrutiocoechea A, Alemany R, Balart J, Villanueva A, Viñals F and Capellá G: Recent advances in cancer: An Overview. Curr Pharm Des. 16:3–10. 2010. View Article : Google Scholar : PubMed/NCBI
2	Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
3	Singh P, Pandit S, Mokkapati VRSS, Garg A, Ravikumar V and Mijakovic I: Gold nanoparticles in diagnostics and therapeutics for human cancer. Int J Mol Sci. 19:19792018. View Article : Google Scholar
4	Baetke SC, Lammers T and Kiessling F: Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol. 88:201502072015. View Article : Google Scholar
5	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–221. 2017. View Article : Google Scholar : PubMed/NCBI
6	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 176:139–148. 2013.
8	Loebinger M, Sage E, Davies D and Janes S: TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer. 103:1692–1697. 2010. View Article : Google Scholar : PubMed/NCBI
9	Liu X, Hu J, Li Y, Cao W, Wang Y, Ma Z and Li F: Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model. Oncol Lett. 15:6265–6274. 2018.
10	Matosevic S: Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J Immunol Res. 2018:40548152018. View Article : Google Scholar : PubMed/NCBI
11	Friedenstein AJ, Gorskaja JF and Kulagina NN: Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 4:267–274. 1976.
12	Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
13	Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S and Takahashi TA: Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy. 6:543–553. 2004. View Article : Google Scholar : PubMed/NCBI
14	Karp JM and Leng Teo GS: Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell. 4:206–216. 2009. View Article : Google Scholar
15	Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
16	Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W and Chayama K: Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer. 127:2323–2333. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yu JM, Jun ES, Bae YC and Jung JS: Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev. 17:463–473. 2008. View Article : Google Scholar : PubMed/NCBI
18	Pan G, O'Rourke K, Chinnaiyan A, Gentz R, Ebner R, Ni J and Dixit V: The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI
19	Wong SHM, Kong WY, Fang CM, Loh HS, Chuah LH, Abdullah S and Ngai SC: The TRAIL to cancer therapy: Hindrances and potential solutions. Crit Rev Oncol Hematol. 143:81–94. 2019. View Article : Google Scholar
20	Nicolini A, Carpi A and Rossi G: Cytokines in breast cancer. Cytokine Growth Factor Rev. 17:325–337. 2006. View Article : Google Scholar : PubMed/NCBI
21	Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
22	Gonzalez-Villarreal C, Rodriguez M and Said-Fernández S: How desirable and undesirable features of naïve or genetically reengineered mesenchymal stem cells are being considered in preclinical or clinical assays. J BUON. 22:812–830. 2017.PubMed/NCBI
23	Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ and Lahn BT: Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One. 5:3–6. 2010. View Article : Google Scholar
24	Kim MH, Billiar TR and Seol DW: The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun. 321:930–935. 2004. View Article : Google Scholar : PubMed/NCBI
25	Yan C, Li S, Li Z, Peng H, Yuan X, Jiang L, Zhang Y, Fan D, Hu X, Yang M and Xiong D: Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: A double-target therapy against non-Hodgkin's lymphoma. Mol Pharm. 10:142–151. 2013. View Article : Google Scholar : PubMed/NCBI
26	Stern B, Olsen LC, Tröße C, Ravneberg H and Pryme IF: Improving mammalian cell factories: The selection of signal peptide has a major impact on recombinant protein synthesis and secretion in mammalian cells. Trends Cell Mol Biol. 10:19–24. 2007.
27	Yuan Z, Kolluri KK, Sage EK, Gowers KH and Janes SM: Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy. Cytotherapy. 17:885–896. 2015. View Article : Google Scholar : PubMed/NCBI
28	Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick S, Ingrao J, Klassen-Ross T, Lacroix-Fralish ML, et al: Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 7:447–449. 2010. View Article : Google Scholar : PubMed/NCBI
29	Committee on Rodents, Institute of Laboratory Animal Resources, Commission on Life Sciences and the National Research Council, . Laboratory Animal Managent Rodents. National Academies Press; Washington, D.C., USA: pp. 991996
30	Bankert RB, Egilmez NK and Hess SD: Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 22:386–393. 2001. View Article : Google Scholar
31	Haouzi P: Murine models in critical care research. Crit Care Med. 39:2290–2293. 2011. View Article : Google Scholar : PubMed/NCBI
32	Frese K and Tuveson D: Maximizing mouse cancer models. Nat Rev Cancer. 7:654–658. 2007. View Article : Google Scholar
33	Boxall SA and Jones E: Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int. 2012:9758712012. View Article : Google Scholar
34	Darzi S, Werkmeister JA, Deane JA and Gargett CE: Identification and characterization of human endometrial mesenchymal stem/stromal cells and their potential for cellular therapy. Stem Cells Transl Med. 5:1127–1132. 2016. View Article : Google Scholar : PubMed/NCBI
35	Li Q, Hou H, Li M, Yu X, Zuo H, Gao J, Zhang M, Li Z and Guo Z: CD73⁺ Mesenchymal stem cells ameliorate myocardial infarction by promoting angiogenesis. Front Cell Dev Biol. 9:6372392021. View Article : Google Scholar
36	Song N, Gao L, Qiu H, Huang C, Cheng H, Zhou H, Lv S, Chen L and Wang J: Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant. Int J Mol Med. 36:139–149. 2015. View Article : Google Scholar : PubMed/NCBI
37	Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, Bosco R, Ingrao S, Zavan B and Zauli G: Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-hodgkin's lymphoma xenografts. PLoS One. 5:e111402010. View Article : Google Scholar : PubMed/NCBI
38	Tu E, Chia PZC and Chen W: TGFβ in T cell biology and tumor immunity: Angel or devil? Cytokine Growth Factor Rev. 25:423–435. 2014. View Article : Google Scholar : PubMed/NCBI
39	Yuen GJ, Demissie E, Pillai S and Burnet M: B lymphocytes and cancer: A love-hate relationship. Trends Cancer. 2:747–757. 2017. View Article : Google Scholar
40	Soussi T: p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res. 60:1777–1788. 2000.PubMed/NCBI
41	Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV and Chudakov DM: B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 20:294–307. 2020. View Article : Google Scholar
42	Lei H, Furlong PJ, Jin HR, Mullins D, Cantor R, Fraker DL and Spitz FR: AKT activation and response to interferon-β in human cancer cells. Cancer Biol Ther. 4:709–715. 2005. View Article : Google Scholar : PubMed/NCBI
43	Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD and Ponnazhagan S: Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model. Gene Ther. 15:1446–1453. 2008. View Article : Google Scholar : PubMed/NCBI
44	Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D and Fidler IJ: Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res. 59:872–879. 1999.PubMed/NCBI
45	Pestka S and Langer JA: Interferons and their actions. Ann Rev Biochem. 56:727–777. 1987. View Article : Google Scholar : PubMed/NCBI
46	Qin X, Runkel L, Deck C, Dedios C and Barsoum J: Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interf Cytokine Res. 17:355–367. 1997. View Article : Google Scholar
47	Kavrochorianou N, Markogiannaki M and Haralambous S: IFN-β differentially regulates the function of T cell subsets in MS and EAE. Cytokine Growth Factor Rev. 30:47–54. 2016. View Article : Google Scholar : PubMed/NCBI
48	Teige I, Liu Y and Issazadeh-Navikas S: IFN-β Inhibits T cell activation capacity of central nervous system APCs. J Immunol. 177:3542–3553. 2006. View Article : Google Scholar
49	Makowska A, Wahab L, Braunschweig T, Kapetanakis NI, Vokuhl C, Denecke B, Shen L, Busson P and Kontny U: Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway. Oncotarget. 9:14228–14250. 2018. View Article : Google Scholar
50	Vannucchi S, Chiantore MV, Fiorucci G, Percario ZA, Leone S, Affabris E and Romeo G: TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-β in cervical carcinoma cells. Oncogene. 24:2536–2546. 2005. View Article : Google Scholar : PubMed/NCBI
51	Yang J, LeBlanc FR, Dighe SA, Hamele CE, Olson TL, Feith DJ and Loughran TP: TRAIL mediates and sustains constitutive NF-kB activation in LGL leukemia. Blood. 131:2803–2815. 2018. View Article : Google Scholar : PubMed/NCBI
52	Mühlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J and Wajant H: The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem. 275:32208–32213. 2000. View Article : Google Scholar
53	Wang CY, Guttridge DC, Mayo MW and Baldwin AS: NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 19:5923–5929. 1999. View Article : Google Scholar
54	Baetu TM, Kwon H, Sharma S, Grandvaux N and Hiscott J: Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol. 167:3164–3173. 2001. View Article : Google Scholar
55	Shetty S, Brown Gladden J, Henson ES, Hu X, Villanueva J, Haney N and Gibson SB: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis. 7:413–420. 2002. View Article : Google Scholar : PubMed/NCBI
56	Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D and Wiley SR: IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol. 163:920–926. 1999.
57	Meng RD and El-Deiry WS: P53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res. 262:154–169. 2001. View Article : Google Scholar : PubMed/NCBI
58	Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, et al: Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene. 22:1653–1662. 2003. View Article : Google Scholar : PubMed/NCBI
59	Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS and Spitz FR: Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res. 63:5299–5307. 2003.PubMed/NCBI
60	Bao Q, Zhao Y, Niess H, Conrad C, Schwarz B, Jauch KW, Huss R, Nelson PJ and Bruns CJ: Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Stem Cells Dev. 21:2355–2363. 2012. View Article : Google Scholar : PubMed/NCBI
61	Taraballi F, Pasto A, Bauza G and Varner C: Immunomodulatory potential of mesenchymal stem cell role in diseases and therapies: A bioengineering prospective. J Immunol Regen Med. 4:1000172019.
62	Monteran L and Erez N: The Dark side of fibroblasts: Cancer-Associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 10:18352019. View Article : Google Scholar
63	Yu P and Fu YX: Tumor-infiltrating T lymphocytes: Friends or foes? Lab Investig. 86:231–245. 2006. View Article : Google Scholar : PubMed/NCBI
64	Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, Vincenzi B, Calò V, Iovanna JL, Bazan V and Russo A: Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol. 343:1037532019. View Article : Google Scholar